Core 3: Specimen Core The Specimen Core has been developed to meet the needs of investigators involved in the projects and pilot studies of the Pacific Ovarian Cancer Research Consortium (POCRC) with respect to tissue acquisition and histologic review, biomarker assay development, and the facilitation of specimen distribution. In addition, a primary goal of the Specimen Core is the development of a large ovarian tissue repository that will ultimately serve as a resource for scientists outside the realm of the POCRC. The advantages of an organized and comprehensive approach to tissue collection and characterization are two fold. First, a systematic process for specimen collection and review will ensure quality and consistency in pathologic analyses. Second, the centralized of specimens will facilitate their distribution based upon the priorities defined by a panel of investigators with all POCRC research endeavors. The research laboratory associated with this core will be responsible for the histologic characterization of all tissue samples collected and stored in the repository. It will also conduct immunohistochemical assays for HER2/neu, Myc, p53, and EGFR as well as screen all tissues for mutations in the p53 gene. This laboratory will also provide consultation and scientific assistance to POCRC laboratories developing potential ovarian cancer screening assays based on currently funded work (Use of Novel Technologies to Identify and Investigate Molecular Markers of Ovarian Cancer Screening and Prevention, 10/98-9/00 DAMD 17-98-1- 8649; N. Urban, PI). Following the development and validation of these novels assays, the core laboratory will run these and other assays on several hundred sera in support of Projects 3 and Project 4. It will also be responsible for meeting the specimen collection and processing needs of Projects 1,2, and 5 and several developmental projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083636-04
Application #
6666316
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-30
Project End
2003-09-29
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998

Showing the most recent 10 out of 187 publications